This Biotech Was Quietly Bought Before a $58 Per Share Takeout | The Motley Fool
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.

Source: The Motley Fool
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.